Topographically Controlled Stereoselectivity
A R T I C L E S
Scheme 1
â-substituted γ-amino acid derivatives 4, of which Baclofen and
Rolipram1,7 are well-known commercial drugs. Of special
interest to us are transformations of pyroglutamic acid to a
family of sterically constrained â-substituted amino acids 5-111
that serve as indispensable ø-(chi)-constrained8-10 scaffolds in
the de novo design of peptides and peptidomimetics with a
predetermined three-dimensional structure.10
induction at both R- and â-positions of the resultant glutamic
acid derivatives were obtained. Surprisingly, an alternative
strategy, i.e., utilization of chiral derivatives of R,â-unsaturated
carboxylic acids in reactions with achiral glycine equivalents,
remains virtually unexplored.2a
To realize the full outstanding synthetic potential of â-sub-
stituted glutamic/pyroglutamic acids, we set a goal of developing
simple, room-temperature, organic-base-catalyzed asymmetric
Michael addition reactions, featuring a virtually complete
stereochemical outcome under operationally conVenient condi-
tions.11 In literature examples, formation of highly organized
Li-chelated transition states at low temperatures was shown to
be necessary to attain high diastereoselectivity in these addition
reactions.2f,k Therefore, the development of room-temperature,
highly diastereoselective Michael additions using a nonchelating
organic base was a challenging task. Our original idea was that
high diastereoselectivity in these reactions could be obtained
by providing geometric ((E)- or (Z)-enolates only) homogeneity
of the glycine enolate and conformational (s-cis or s-trans only)
homogeneity of the Michael acceptor. This led to a method-
ologic breakthrough12 in the development of room-temperature,
organic-base-catalyzed Michael addition reactions.
Over the last several years, we have reported on the design
and synthesis of the o-aminoacetophenone- and -benzophenone-
derived Ni(II) complexes of glycine 12a,b (Scheme 2) as
chemically stable yet highly reactive nucleophilic glycine
equivalents.13 Their superior synthetic quality over the conven-
tionally used Schiff base 13 for preparation of sterically
constrained R,R-dialkyl-R-amino acids was demonstrated.14
Glycine derivatives 12a,b were found to be particularly useful
in Michael addition reactions with chiral acceptors 14, allowing
preparation of the corresponding â-substituted glutamic/pyro-
glutamic acids, via the intermediate adducts 15, with high
chemical yield and optical purity.15 For instance, use of Schiff
base 13 in addition reactions with 14 was disappointing and
Among the various methods available in the literature,
Michael addition of nucleophilic glycine equivalents to â-sub-
stituted acrylic acid derivatives offers a methodologically concise
and synthetically attractive route to the corresponding â-sub-
stituted pyroglutamic acids 1. The asymmetric version of this
reaction has been the focus of a number of research groups,
and methods to control simultaneous formation of two stereo-
genic centers have been developed.2,3 Common drawbacks of
the literature methods include incomplete (<95% enantiomeric
excess (ee)) stereochemical outcome and chemical yield, the
need for strong bases such as BuLi to generate the corresponding
enolate, and the need to perform the reactions at -78° C, which
diminish the attractiveness of these methods. Analysis of the
relevant literature1-3 reveals that, thus far, only one strategy to
control the stereochemical outcome in these reactions has been
explored. In this approach, addition reactions with chiral glycine
equivalents and R,â-unsaturated carboxylic acid derivatives were
studied, and in some cases, reasonably high levels of asymmetric
(4) (a) Somfia, P.; Ahman, J. Tetrahedron Lett. 1992, 33, 3791. (b) Ahman,
J.; Somfia, P. Tetrahedron 1992, 48, 9537. (c) Melching, K. H.; Hiemstra,
H.; Klaver, W. J.; Speckamp, W. N. Tetrahedron Lett. 1986, 27, 4799.
(5) (a) Provot, O.; Celerier, J. P.; Petit, H.; Lhommet, G. J. Org. Chem. 1992,
57, 2163. (b) Karstens, W. F.; Stol, M.; Rutjes, F. P.; Hiemstra, H. Synlett
1998, 1126.
(6) (a) Wang, W.; Yang, J.; Ying, J.; Xiong, C.; Zhang, J.; Cai, C.; Hruby, V.
J. J. Org. Chem. 2002, 67, 6353. (b) Lim, S. H.; Ma, S.; Beak, P. J. Org.
Chem. 2001, 66, 9056.
(7) (a) Garcia, A. L. L.; Carpes, M. J. S.; de Oca, A. C. B. M.; dos Santos, M.
A. G.; Santana, C. C.; Correia, C. R. D. J. Org. Chem. 2005, 70, 1050-
1053. (b) Chang, M.-Y.; Chen, C.-Y.; Tasi, M.-R.; Tseng, T.-W.; Chang,
N.-C. Synthesis 2004, 840-846. As pointed out by a referee, “according
to the Investigational Drug database (IDdb3) and as of March 24, 2004,
the development of Rolipram was discontinued by Meiji Seika (Japan) and
Schering, A. G. (Germany)”.
(8) For recent reviews on ø-constrained amino acids, see: (a) Gibson, S. E.;
Guillo, N.; Tozer, M. J. Tetrahedron 1999, 55, 585. (b) Hruby, V. J.; Li,
G.; Haskell-Luevano, C.; Shenderovich, M. D. Biopolymers 1997, 43, 219.
(9) For the recent collection of leading papers, see: Asymmetric Synthesis of
Novel Sterically Constrained Amino Acids. Tetrahedron Symposia-in-Print,
#88. Guest Editors: Hruby, V. J., Soloshonok, V. A. Tetrahedron 2001,
57, no. 30.
(11) In the current literature, one can notice a trend for a paradigm of the
synthetic methodology of the future, which is simplicity of experimental
conditions or, as we call it, operationally convenient reaction conditions.
(12) (a) Soloshonok, V. A.; Cai, C.; Hruby, V. J. Tetrahedron Lett. 2000, 41,
135. (b) Soloshonok, V. A.; Cai, C.; Hruby, V. J.; Meervelt, L. V.;
Yamazaki, T. J. Org. Chem. 2000, 20, 6688.
(13) For large-scale synthesis of Ni(II) complexes 12a,b, see: Ueki, H.; Ellis,
T. K.; Martin, C. H.; Soloshonok, V. A. Eur. J. Org. Chem. 2003, 1954.
(14) (a) Ellis, T. K.; Martin, C. H.; Ueki, H.; Soloshonok, V. A. Tetrahedron
Lett. 2003, 4, 1063-1066. (b) Ellis, T. K.; Martin, C. H.; Tsai, G. M.;
Ueki, H.; Soloshonok, V. A. J. Org. Chem. 2003, 68, 6208-6214. (c) Ellis,
T. K.; Hochla, V. M.; Soloshonok, V. A. J. Org. Chem. 2003, 68, 4973-
4976.
(10) (a) Hruby, V. J. Life Sci. 1982, 31, 189. (b) Hruby, V. J.; Al-Obeidi, F.;
Kazmierski, W. M. Biochem. J. 1990, 268, 249. (c) Hruby, V. J.
Biopolymers 1993, 33, 1073. (d) Cai, M.; Cai, C.; Mayorov, A. V.; Xiong,
C.; Cabello, C. M.; Soloshonok, V. A.; Swift, J. R.; Trivedi, D.; Hruby, V.
J. J. Pept. Res. 2004, 63, 116.
9
J. AM. CHEM. SOC. VOL. 127, NO. 43, 2005 15297